Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Inclusion Criteria: * Histologically or cytologically confirmed sarcoma, including any of the following neoplastic subtypes: * Giant hemangioma * Angiosarcoma (including epithelioid hemangioendothelioma) * Malignant peripheral nerve sheath tumor * Leiomyosarcoma (closed to accrual as of 11/29/06) * High-grade undifferentiated pleomorphic sarcoma (i.e., malignant fibrous histiocytoma \[including myxofibrosarcoma\]) (closed to accrual as of 11/29/06) * Synovial sarcoma (closed to accrual as of 11/29/06) * Carcinosarcoma (closed to accrual as of 11/29/06) * Metastatic, locally advanced, or locally recurrent disease * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * Lesions in a previously irradiated area may be considered measurable provided there is evidence of subsequent disease progression that cannot be attributed to necrosis or bleeding * No gastrointestinal stromal tumor * No known brain metastases * Performance status - ECOG 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No evidence of bleeding diathesis * Bilirubin ≤ 1.5 mg/dL * INR ≤ 1.5 * AST and ALT ≤ 2.5 times upper limit of normal * Creatinine ≤ 1.5 mg/dL * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * No uncontrolled hypertension * No history of allergic reaction to compounds of similar chemical or biologic composition to sorafe…